History
In October 2006 ONELIFE (Onelife Advisors SA) was founded in response to the financial community requiring a deeper knowledge of the Life Science sector. Enrico Braglia (Onelife Founder) has more that 20 years of experience in chemical and pharmaceutical industry and assumed direct responsibility on many international projects.
In 2007, ONELIFE participated to several international projects, including the set-up, advisory and management of PROSPERA SENECTUTE FUND (SICAF-SIF) a Luxembourg Life Science investment fund focused on aging. The fund has an ethical investment approach. Onelife also analyzed several in-out licensing projects for selected clients, helped financial institutions on Life Science investments and collaborated with several non-profit organizations to help elderly people and support research in the geriatric field,
In 2008, ONELIFE continued its collaboration with institutional partners and pharmaceutical companies. The most challenging project was to set up a new biopharmaceutical company engaged in the research and development of therapies for neurodegenerative disorders (www.senexta.com
In 2009, ONELIFE supported Senexta in designing its development strategy. The CMC section, the preclinical was successfully completed obtaining an FDA IND. A new clinical regulatory study was designed and initiated. ONELIFE also worked together with several other start-ups company and with some investors in indentifying the best path and strategy.
In 2010, ONELIFE launch the new platform Bench-2-Bed. This platform is designed for Life Sciences start-up company to reach quickly the clinical stage at very low cost. ONELIFE also has signed an Advisory Agreement for a new Private Equity Fund (Bright Technologies Fund). First investment was the Swiss Chemical company HeiQ.
During 2011, ONELIFE was involved in several scouting and evaluation projects for its partners. This leads to some M&A activity, investment and partnership. A new investment was added to Bright Technologies Fund: elmove AG